alexa
Reach Us +1-217-403-9671
Regulatory Strategy For Similar Biologics In India | 7540
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Regulatory strategy for similar biologics in India

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Katla Sirisha and T.M. Pamod Kumar

Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.008

Abstract
The objective of this paper is to provide guidelines to applicants to enable them to understand and comply with the regulatory requirements for the authorization of similar biologics in India. The CDSCO is the national regulatory authority in India that evaluates safety, efficacy and quality of drugs in the country. The DBT through Review Committee on Genetic Manipulation (RCGM) is responsible for overseeing the development and preclinical evaluation of recombinant biologics. There are several such products under development in India, both regulatory agencies considered the need to publish a clear regulatory pathway outlining the requirements to ensure comparable safety, efficacy and quality of a similar biologic to an authorized reference biologic. A similar biologic may require reduced preclinical and clinical data package as part of submission for market authorization. The similar biologics are regulated as per the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945 (as amended from time to time) and Rules for the manufacture, use, import, export and storage of hazardous microorganisms/genetically engineered organisms or cells, 1989 (Rules, 1989) notified under the Environment (Protection) Act, 1986. Various applicable guidelines are Recombinant DNA safety guidelines, 1990 guidelines for generating preclinical and clinical data for rDNA vaccines, diagnostics and other biological, 1999, cdsco guidance for industry. Competent authorities involved in the approval process are Review committee on genetic manipulation (RCGM) genetic engineering appraisal committee (GEAC) Central Drugs Standard control Organisation (CDSCO). Thus all the global pharmaceutical companies should follow up the guidelines approved for biologics by CDSCO for marketing authorisation in India.
Biography
katla. sirisha pursuing m.pharm 1st year with specialisation in regulatory affairs in jss college of pharmacy, jss university Mysore, I have completed my b.pharm degree in Siddhartha institute of pharmaceutical sciences, Guntur.
Top